Discovering IFT74: A Potential Drug Target Or Biomarker for Cancer

Target Name: IFT74

NCBI ID: G80173

IFT74

Discovering IFT74: A Potential Drug Target Or Biomarker for Cancer

IFT74 (JBTS40), a protein that is expressed in human tissues, has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer. The discovery of IFT74 as a potential drug target is based on its unique structure and its expression pattern in various human tissues.

IFT74 is a protein that is expressed in various human tissues, including the brain, heart, liver, and pancreas. It is a member of the IFT family, which includes several similar proteins that are involved in various cellular processes. IFT74 is unique in its structure, as it has a molecular weight of 40 kDa and a calculated pI of 6.5.

The pI of a protein is a measure of its stability in various environments, including the extracellular matrix (ECM) and the intracellular fluid (ICF). A protein with a low pI is more stable in the ECM, while a protein with a high pI is more stable in the ICF. IFT74 has a calculated pI of 6.5, which suggests that it is more stable in the ICF than in the ECM.

The structure of IFT74 is also unique, as it has a alternating and open loop region. The alternating loop region is located in the N-terminus of the protein and is responsible for its unique structure. The open loop region is located in the C-terminus of the protein and is involved in the interaction of IFT74 with other proteins.

IFT74 has been shown to play a role in various cellular processes, including cell signaling, cell adhesion, and cell survival. It has been shown to interact with several proteins, including the protein p53. The interaction between IFT74 and p53 has been shown to play a role in the regulation of cellular processes, including cell growth, apoptosis, and cancer progression.

IFT74 has also been shown to be involved in the regulation of cellularmetabolic processes, including cell energy metabolism and cell metabolism. It has been shown to interact with several metabolic enzymes, including the enzyme succinyl-CoA synthase (SCS). The interaction between IFT74 and SCS has been shown to play a role in the regulation of cellular energy metabolism and the risk of cancer.

IFT74 has also been shown to be involved in the regulation of cellular immune responses, including the regulation of T cell activity. It has been shown to interact with several immune molecules, including the protein PD-L1. The interaction between IFT74 and PD-L1 has been shown to play a role in the regulation of cellular immune responses and the risk of cancer.

In conclusion, IFT74 (JBTS40) is a unique protein that has been shown to play a role in various cellular processes, including cell signaling, cell adhesion, cell survival, cellular metabolism, and cellular immune responses. Its unique structure and its interaction with other proteins have make it a potential drug target or biomarker for the treatment of various diseases, including cancer. Further research is needed to fully understand the role of IFT74 in cellular processes and its potential as a drug target or biomarker.

Protein Name: Intraflagellar Transport 74

Functions: Component of the intraflagellar transport (IFT) complex B: together with IFT81, forms a tubulin-binding module that specifically mediates transport of tubulin within the cilium (PubMed:23990561). Binds beta-tubulin via its basic region (PubMed:23990561). Required for ciliogenesis (PubMed:23990561). Essential for flagellogenesis during spermatogenesis (PubMed:33689014)

The "IFT74 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IFT74 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets